Press Releases April 20, 2026 06:00 AM

Tower Semiconductor Announces First Quarter 2026 Financial Results and Conference Call

Tower Semiconductor schedules Q1 2026 earnings release and conference call for May 13, 2026

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
TSEM

Tower Semiconductor announced it will release its Q1 2026 financial results on May 13, 2026, and hold a conference call to discuss the results and provide Q2 guidance. The company is a leading foundry specializing in analog semiconductor solutions, serving multiple high-growth markets with diverse technology platforms and global manufacturing facilities.

Tower Semiconductor Announces First Quarter 2026 Financial Results and Conference Call
TSEM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 financial results and Q2 2026 guidance announcement scheduled for May 13, 2026.
  • Tower Semiconductor is a leader in high-value analog semiconductor foundry services across various technology platforms including SiGe, BiCMOS, CMOS, RF CMOS, and MEMS.
  • The company operates manufacturing facilities in Israel, the U.S., Japan, and Italy, supporting diverse markets like consumer, automotive, industrial, and aerospace sectors.

MIGDAL HAEMEK, Israel – April 20, 2026 – Tower Semiconductor (NASDAQ/ TASE: TSEM), the leading foundry of high value analog semiconductor solutions, will issue its first quarter 2026 earnings release on Wednesday, May 13, 2026. The Company will hold a conference call to discuss its first quarter 2026 financial results and second quarter 2026 guidance on Wednesday, May 13, 2026, at 10:00 a.m. Eastern Time (09:00 a.m. Central, 08:00 a.m. Mountain, 07:00 a.m. Pacific and 05:00 p.m. Israel time).

The call will be webcast and available through the Investor Relations section of Tower Semiconductor’s website at https://ir.towersemi.com/, where the pre-registration form required for dial-in participation is also accessible. Upon completing the registration, participants will receive the dial-in details, a unique PIN, and a confirmation email with all necessary information. The teleconference will be available for replay for 90 days.

About Tower Semiconductor         

Tower Semiconductor Ltd. (NASDAQ/TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, provides technology, development, and process platforms for its customers in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical and aerospace and defense. Tower Semiconductor focuses on creating a positive and sustainable impact on the world through long-term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, displays, integrated power management (BCD and 700V), photonics, and MEMS. Tower Semiconductor also provides world-class design enablement for a quick and accurate design cycle as well as process transfer services including development, transfer, and optimization, to IDMs and fabless companies. To provide multi-fab sourcing and extended capacity for its customers, Tower Semiconductor owns one operating facility in Israel (200mm), two in the U.S. (200mm), two in Japan (200mm and 300mm) which it owns through its 51% holdings in TPSCo and shares a 300mm facility in Agrate, Italy with STMicroelectronics. For more information, please visit: www.towersemi.com.

###
Contact Information:
Liat Avraham
Investor Relations
[email protected] | +972 4 650 6154

Attachment

  • TSEM_Tower_Q12026_PRDate_1

Risks

  • Uncertainty around Q1 2026 financial performance, which could impact investor sentiment.
  • Potential supply chain or operational risks affecting production capacity in global manufacturing sites.
  • Market volatility and competitive pressures in the semiconductor industry impacting future growth prospects.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026